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 Borderline personality disorder (BPD) is one of the most prevalent, and most disabling, 
personality disorders. There is increasing consensus that the disorder is characterized by three 
related core features: severe emotion dysregulation, strong impulsivity, and social-
interpersonal dysfunction.1 Individuals diagnosed with BPD were historically considered to 
be “hard to reach” and pessimism with regard to treatment prevailed. This view has changed 
over the past two decades, mainly as a result of emerging evidence for the efficacy and cost-
effectiveness of specialized psychotherapies for individuals with BPD.2,3  
 
The study by Cristea and colleagues4 in this issue represents a new and major leap forward in 
this regard, as it heralds the coming of age of research on the effectiveness of psychotherapy 
for BPD. Cristea et al. report a meta-analysis including 33 studies of specialized 
psychotherapy either as a standalone treatment or as an add-on to non-specialized 
psychotherapies in adult patients diagnosed with BPD. Overall, specialized psychotherapy 
emerges as moderately more effective than non-specialized psychotherapy in reducing 
borderline-relevant and other outcomes, such as general psychopathology and service 
utilization, with no differences between specialized psychotherapy as a standalone or as an 
add-on to usual treatment. Importantly, these effects were typically maintained up to 2-year 
follow-up. Very few adverse events were reported, suggesting that psychotherapy for BPD is 
both effective and safe. With regard to the different treatment approaches, dialectical 
behavior therapy (DBT) and psychodynamic therapy emerged as more effective than non-
specialized psychotherapy or treatment as usual (TAU); no such differences were found for 
cognitive therapy and other interventions. However, there was evidence of risk of bias in 
published studies and publication bias, particularly with regard to studies reporting follow-up 
data. 
 While these findings provide further support for the cautious optimism with regard to the role 
of specialized psychotherapy (and psychotherapy more generally) in treating BPD, Cristea et 
al.’s meta-analysis also highlights important limitations and concerns that the field needs to 
urgently address. 
 
Cristea et al. found that differences between specialized and non-specialized therapies, 
although significant, were small to moderate, suggesting only a slight advantage of 
specialized psychotherapy. In fact, correcting for publication bias by adjusting effect sizes for 
missing studies led to even smaller differences, which disappeared on follow-up. 
Furthermore, studies that used strong control conditions (e.g., with ad hoc developed control 
treatments and/or manualized treatments such as structured clinical management (SCM)) 
showed no significant differences between specialized psychotherapy and control conditions.  
Do these findings mean that specialized psychotherapies are actually no more effective than 
non-specialized psychotherapy? Perhaps, particularly as Cristea et al. speculate that the 
superior outcomes of specialized treatments and strong control conditions could be explained 
by the “special attention” BPD patients received in such studies. Yet, the authors also raise 
the possibility that the superiority of these outcomes is rooted in their highly structured and 
often carefully manualized design. Consistent with this, we have argued that the coherence, 
consistency, and continuity of specialized treatments for BPD are crucial because they 
provide cognitive structure for a patient group that lacks metacognitive organization.5 The 
importance of structuring of subjective experience as part of treatment has influenced how 
therapists—including the therapists in the TAU arm of trials—work with patients with BPD, 
so outcomes may have improved in TAU because iatrogenesis is likely to have decreased 
with the waning of unfocused exploratory and supportive interventions.6 Control conditions, 
particularly those in more recent trials, thus were not truly “non-specialized” treatments with 
smaller effects. If this is true, not only is it evidently good news for patients and clinicians; it 
would also point to how interventions could be made simpler without compromising their 
effectiveness. The finding that treatment intensity, in terms of duration and hours of therapy, 
was not related to outcomes also suggests further changes could be made to the current 
complex and long term specialist treatments without losing effectiveness. 
 
Recommendations based on the Cristea et al. meta-analysis are to some measure determined 
by inclusion criteria, as direct comparisons of active treatments were excluded, based on the 
premise that few, if any, differences between specialized psychotherapies for BPD can be 
expected. Yet, this decision may have disadvantaged specific types of specialized 
psychotherapies, such as schema-focused therapy and general psychiatric management, 
which have been mostly investigated in studies comparing these versus other active 
treatments. Furthermore, while clustering of treatment types such as TFP and MBT under the 
heading of psychodynamic therapies, may be appropriate from some perspectives (the 
orientation of the developers), it makes less sense from others (e.g., the length of training 
required for each). Lumping treatments together may obscure potential differences in 
effectiveness (are all “cognitive-behavioral” therapies the same?). Modality labels may 
simplify—and suit payers—but are scientifically unsound if they are not directly linked to 
change mechanisms. Our focus on labels of convenience obscures understanding of 
mechanisms, which is the sole path to increase the effectiveness of BPD therapies.7  
 
The validity of meta-analytic results is invariably threatened by unknown comorbidity and 
excessive within-diagnosis heterogeneity—and rarely more so than with BPD, where 
diagnosis is challenged by high temporal instability and poor convergent and discriminant 
validity.8 The various evidence-based treatments included in the present meta-analysis may 
have studied different populations and thus may be differentially effective in different 
subtypes of BPD. For example, MBT was superior over SCM only in BPD patients with 
multiple Axis II diagnoses.9 
 
Yet, at the same time, the subtyping of BPD has been relatively unsuccessful. Multilevel 
factor analytic studies of personality disorder symptoms have suggested that BPD may be 
most parsimoniously seen as part of a “general personality disorder” factor rather than one of 
a number of personality disorder diagnoses.10 If BPD is largely an indicator of vulnerability 
to personality disorder diagnoses, then perhaps we are wrong to think about BPD as a 
disorder; rather, we could conceive of its core symptoms as indications of a relative lack of 
capacity to withstand adversity. The “specialist” therapies found to be effective in BPD may 
have in common an unwavering and consistent focus on this core feature of BPD, which 
brings about improvements. More research is needed to substantiate these assumptions, 
however. 
 
We were surprised that Cristea et al. found no evidence that the developers of specialized 
psychotherapies produced superior outcomes to replication studies—in contrast to a pattern 
that has been well demonstrated in other domains of psychotherapy.11 Its absence may 
suggest a remarkable stability of findings or insufficient replications. The large differences in 
both treatment intensity and duration of psychotherapies for BPD, and the differences in 
training burden entailed for these various therapies, highlight the need for cost-effectiveness 
research. Furthermore, to decrease the risk of publication bias, Cristea et al. rightfully call for 
advanced registration of trials; this could be strengthened if study designs were reviewed by 
journals before results became available, and by triple-blind data analysis of data.12 
 In conclusion, while Cristea et al.’s study will undoubtedly provide a major impetus to future 
research on the effectiveness of psychotherapy for BPD, their findings make it clear that 
much remains to be done in terms of the development, evaluation, and implementation in 
routine clinical care of effective psychotherapy for this highly debilitating condition. 
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